Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
Crossref DOI link: https://doi.org/10.1007/s40273-015-0278-7
Published Online: 2015-05-05
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hoch, Jeffrey S.
Beca, Jaclyn
Sabharwal, Mona
Livingstone, Scott W.
Fields, Anthony L. A.
License valid from 2015-05-05